RCG
RNTX

Rock Creek Group’s Rein Therapeutics RNTX Stock Holding History

Rock Creek Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Buy
125,000
+25,000
+25% +$31K 0.02% 51
2025
Q4 		$116K Buy
+100,000
New +$138K 0.01% 50

Other funds holding RNTX

VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Rock Creek Group's RNTX Position: Q1 2026 in Review

Rock Creek Group increased its Rein Therapeutics (RNTX) stake by 25% in Q1 2026, buying an estimated $31K and bringing the position to 125,000 shares worth $163K. The position accounts for 0.02% of the portfolio, ranked #51.

Rock Creek Group first reported a position in RNTX in Q4 2025 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Rock Creek Group held 125,000 shares of Rein Therapeutics worth $163K as of Q1 2026.
  • Rock Creek Group bought 25,000 Rein Therapeutics shares in Q1 2026, an estimated $31K.
  • Rein Therapeutics made up 0.02% of Rock Creek Group's portfolio in Q1 2026, its #51 holding.
  • Rock Creek Group first reported a position in Rein Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Rock Creek Group's 13F filing for Q1 2026, filed 11 May 2026.